BIOMEA FUSION INC. - COMMON STOCK

Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1 RA-Based Therapy

15 окт 2024 15:05:19 Источник Nasdaq GlobeNewswire

Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)

07 окт 2024 08:00:41 Источник Nasdaq GlobeNewswire

Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts

01 окт 2024 08:00:01 Источник Nasdaq GlobeNewswire

FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials

26 сен 2024 13:00:57 Источник Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

01 авг 2024 15:05:20 Источник Nasdaq GlobeNewswire

Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights

31 июл 2024 15:05:22 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold

06 июн 2024 15:05:53 Источник Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

03 июн 2024 15:05:29 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes

30 май 2024 08:12:39 Источник Nasdaq GlobeNewswire

Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights

02 май 2024 15:05:01 Источник Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 май 2024 15:10:28 Источник Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 апр 2024 15:10:59 Источник Nasdaq GlobeNewswire

Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219

01 апр 2024 08:02:04 Источник Nasdaq GlobeNewswire

Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights

01 апр 2024 08:00:11 Источник Nasdaq GlobeNewswire

Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function

06 мар 2024 02:04:51 Источник Nasdaq GlobeNewswire

Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

01 мар 2024 15:16:34 Источник Nasdaq GlobeNewswire

Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference

09 янв 2024 10:02:26 Источник Nasdaq GlobeNewswire

Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219

08 янв 2024 08:00:26 Источник Nasdaq GlobeNewswire

Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference

02 янв 2024 15:05:00 Источник Nasdaq GlobeNewswire

Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH Annual Meeting

11 дек 2023 08:25:04 Источник Nasdaq GlobeNewswire